Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer.
- DOI
- 10.1016/j.ctarc.2025.100970
- Published
- 2025
- Container
- Cancer treatment and research communications
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ctarc.2025.100970,
title = {Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer.},
author = {Andric Z and Moiseenko F and Makharadze T and Oleksiienko A and Yañez Ruiz E and Kim S and Ahn K and Park T and Ju H and Baek EH and Kwon S and Chang I and Kim S and Kim H and Lee E and Verschraegen C},
year = {2025},
journal = {Cancer treatment and research communications},
doi = {10.1016/j.ctarc.2025.100970},
url = {https://doi.org/10.1016/j.ctarc.2025.100970}
}RIS
TY - JOUR TI - Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer. AU - Andric Z AU - Moiseenko F AU - Makharadze T AU - Oleksiienko A AU - Yañez Ruiz E AU - Kim S AU - Ahn K AU - Park T AU - Ju H AU - Baek EH AU - Kwon S AU - Chang I AU - Kim S AU - Kim H AU - Lee E AU - Verschraegen C PY - 2025 JO - Cancer treatment and research communications DO - 10.1016/j.ctarc.2025.100970 UR - https://doi.org/10.1016/j.ctarc.2025.100970 ER -
APA
Z, A., F, M., T, M., A, O., E, Y. R., S, K., K, A., T, P., H, J., EH, B., S, K., I, C., S, K., H, K., E, L., & C, V. (2025). Long-term results of a randomized controlled trial of biosimilar CT-P16 and reference bevacizumab in patients with metastatic or recurrent non-small cell lung cancer.. Cancer treatment and research communications. https://doi.org/10.1016/j.ctarc.2025.100970
Source records
- pubmed · retrieved 2026-09-27T08:46:14.552Z